they were not allowed to make any comparison with Bactroban given ASX rules. They would not be limited to draw that comparison at the up coming meeting however this is always problematic given that the study was not designed for this reason. If you look at recent data on Bactroban as I have posted here previously the results of this scoping study in comparison with recent published data on bactroban is good if not better
they were not allowed to make any comparison with Bactroban...
-
- There are more pages in this discussion • 7,491 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.015(3.95%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $2.500M | 6.790M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 193164 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 54356 | 4 |
View Market Depth
| Last trade - 14.23pm 19/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |